Biomea Fusion, Inc. (BMEA)
| Market Cap | 42.20M -56.4% |
| Revenue (ttm) | n/a |
| Net Income | -22.31M |
| EPS | -0.31 |
| Shares Out | 72.48M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 563,779 |
| Open | 0.5750 |
| Previous Close | 0.5627 |
| Day's Range | 0.5401 - 0.6000 |
| 52-Week Range | 0.5401 - 2.2370 |
| Beta | -0.14 |
| Analysts | Buy |
| Price Target | 6.17 (+959.26%) |
| Earnings Date | Nov 10, 2026 |
About BMEA
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for BMEA stock is "Buy." The 12-month stock price target is $6.17, which is an increase of 959.26% from the latest price.
News
Biomea Fusion to Participate in Upcoming Investor Conferences
SAN CARLOS, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company, today announced that members of its management team wil...
Biomea Fusion reports Q3 EPS (9c), consensus (23c)
“The third quarter was marked by meaningful execution across both of our clinical programs. We completed enrollment in our first diabetes Phase II clinical trial, COVALENT-211, and continue to advance...
Biomea Fusion Reports Third Quarter 2026 Financial Results and Corporate Highlights
SAN CARLOS, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported i...
Biomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek® 2026
SAN CARLOS, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company focused on diabetes and obesity, today announced that it...
Biomea Fusion Quarterly report: Q3 2026
Biomea Fusion has published its Q3 2026 quarterly earnings report on November 10, 2026.
Biomea Fusion Earnings release: Q3 2026
Biomea Fusion released its Q3 2026 earnings on November 10, 2026, summarizing the period's financial results.
Biomea Fusion Transcript: Study result
In the 28-day phase I study, BMF-650 produced dose-related weight reduction, including 6.1% in the small, confined Cohort 5, with a generally well-tolerated profile. Longer toxicology studies and further dose evaluation are planned ahead of phase II development.
Biomea Fusion Press release: Study result
Biomea Fusion issued a press release on October 13, 2026, disclosing material business information to investors.
Biomea Fusion Slides: Study result
Biomea Fusion has posted slides in relation to its latest quarterly earnings report, which was published on October 13, 2026.
Biomea Fusion announces Phase 1 GLP-131 clinical trial results for BMF-650
Biomea Fusion (BMEA) announced Phase 1 GLP-131 clinical trial results for BMF-650, its investigational oral small-molecule glucagon-like peptide-1 receptor agonist, or GLP-1 RA”, which demonstrated co...
Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist
SAN CARLOS, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company, today announced Phase 1 GLP-131 clinic...
Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist
Company to host conference call and webcast on October 13, 2026, at 4:30 p.m. ET (1:30 p.m. PT) Company to host conference call and webcast on October 13, 2026, at 4:30 p.m. ET (1:30 p.m. PT)
Biomea Fusion initiated with a Buy at Brookline
Brookline analyst Kumaraguru Raja initiated coverage of Biomea Fusion (BMEA) with a Buy rating and $10 price target Biomea is developing icovamenib as a potentially disease-modifying therapy that can ...
Biomea Fusion terminates proposed offering of common stock, warrants
Biomea Fusion (BMEA) announced that it has terminated its proposed public offering of securities, previously announced on September 22. The termination results from an assessment by the company’s mana...
Biomea Fusion Announces Termination of Proposed Public Offering of Securities
SAN CARLOS, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it has termin...
Biomea Fusion announces offering of common stock and warrants, no amount given
Biomea Fusion (BMEA) announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to…
Biomea Fusion Announces Proposed Public Offering of Securities
SAN CARLOS, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, announced today that it has commenced an underwritt...
Biomea Fusion Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The presentation highlighted progress on a first-in-class menin inhibitor for diabetes, showing promising phase II results in both Type 1 and Type 2 diabetes, and a next-generation GLP-1 agent with improved tolerability. Key clinical readouts and potential licensing activities are expected within the next year.
Biomea Fusion completes enrollment in COVALENT-211 trial
Biomea Fusion (BMEA) announced the completion of enrollment in COVALENT-211, a randomized, double-blinded, placebo-controlled Phase II clinical trial evaluating icovamenib in patients with insulin-def...
Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes
SAN CARLOS, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today an...
Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it?
Citi analyst Yigal Nochomovitz sees enormous upside in two biotech stocks, but those forecasts reveal as much about risk as potential reward. Nochomovitz has a $7 target on Biomea Fusion, implying abo...
Biomea Fusion doses first patient in OPAL study
Biomea Fusion (BMEA) announced that the first participant has been dosed in a new arm of the ongoing platform research study, Investigating and Optimizing Physical Function with Weight Loss: A…
Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity
• Initiated Study to Assess the Potential Impact of the Combination of Icovamenib and Low-Dose Semaglutide on Physical Function, Body Weight, Body Composition, Muscle Health, and Metabolic Outcomes
Citi adds ‘upside 90-day catalyst watch’ on Biomea into GLP-1 data
Citi analyst Yigal Nochomovitz added an “upside 90-day catalyst watch” on Biomea Fusion (BMEA) while keeping a Buy rating on the shares with a $7 price target The firm expects…
Biomea Fusion price target lowered to $7 from $9 at Citizens
Citizens lowered the firm’s price target on Biomea Fusion (BMEA) to $7 from $9 and keeps an Outperform rating on the shares. The firm noted that data from the Phase…